C11orf61_BC024479 Inhibitors
C11orf61_BC024479 Inhibitors are a collection of chemical compounds that indirectlyC11orf61_BC024479 Inhibitors are a collection of chemical compounds that indirectly influence the activity of the C11orf61_BC024479 protein by targeting various signaling pathways and enzymes that may regulate or interact with it. LY294002 and Wortmannin, both PI3K inhibitors, lead to decreased AKT phosphorylation, which is a critical step in multiple signaling cascades, including those that may involve C11orf61_BC024479. Since PI3K/AKT signaling is central to a range of cellular processes, the inhibition of this pathway by these compounds can result in the diminished functional activity of C11orf61_BC024479, particularly if it is a downstream effector or is otherwise modulated by PI3K/AKT-mediated signals. Similarly, U0126 and PD98059, which inhibit MEK1/2 within the MAPK/ERK pathway, would lead to reduced activity of ERK, a kinase that phosphorylates various substrates implicated in cell growth and differentiation. If C11orf61_BC024479 is regulated by the MAPK/ERK pathway, the use of these inhibitors would suppress its activity by preventing necessary phosphorylation events or pathway activations.
Other inhibitors such as SB203580 and SP600125 target p38 MAPK and JNK, respectively, both of which are integral to stress and inflammatory responses. Inhibition of these kinases can affect proteins that are part of these signaling networks, reducing the functional activity of C11orf61_BC024479 if it is linked to these pathways. Rapamycin, by inhibiting mTOR, could decrease the activity of proteins in growth and proliferation pathways that C11orf61_BC024479 may modulate. In contrast, Y-27632 disrupts the Rho/ROCK pathway, affecting cytoskeletal organization and potentially influencing C11orf61_BC024479 activity if it interacts with cytoskeletal-associated proteins or processes. Go6983's inhibition of PKC isoforms could lead to reduced C11orf61_BC024479 activity due to a decrease in PKC-mediated signaling, while SB216763 targets GSK-3, which could attenuate the activity of C11orf61_BC024479 by affecting Wnt signaling or other GSK-3 regulated pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of PI3K. C11orf61_BC024479, involved in PI3K/AKT signaling, would have its activity reduced as LY294002 inhibits PI3K, resulting in decreased phosphorylation of downstream targets, including proteins that C11orf61_BC024479 may regulate or interact with. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A specific inhibitor of p38 MAPK. By inhibiting p38 MAPK, SB203580 would prevent the activation of downstream proteins targeted by p38 MAPK, which could include those regulated by or interacting with C11orf61_BC024479, thereby inhibiting C11orf61_BC024479's function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A selective inhibitor of JNK. The inhibition of JNK activity can disrupt signaling pathways that C11orf61_BC024479 may be a part of, leading to the inhibition of C11orf61_BC024479's functional activity due to the lack of JNK-mediated phosphorylation or other regulatory mechanisms. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor which would inhibit downstream signaling pathways of mTOR. Since C11orf61_BC024479 could be involved in these pathways, the inhibition of mTOR by rapamycin would lead to decreased activity of proteins regulated by mTOR, potentially including C11orf61_BC024479. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
A Src family kinase inhibitor. If C11orf61_BC024479's activity is modulated by Src kinase signaling, inhibition by PP2 would lead to decreased Src kinase activity and thus a decrease in C11orf61_BC024479's activity due to reduced phosphorylation or other regulatory interactions. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A specific inhibitor of MEK, which blocks the MAPK/ERK pathway. By inhibiting MEK, PD98059 would limit ERK activation, potentially affecting C11orf61_BC024479 if it is regulated by or associated with the MAPK/ERK pathway, thus leading to decreased functional activity of C11orf61_BC024479. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor similar to LY294002. Wortmannin's inhibition of PI3K would lead to a reduction in AKT phosphorylation and activity, potentially affecting signaling pathways that C11orf61_BC024479 is involved in, thereby leading to a decrease in C11orf61_BC024479's functional activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that impedes the Rho-associated protein kinase pathway. By inhibiting ROCK, Y-27632 would decrease the phosphorylation of downstream targets within the pathway, potentially including targets regulated by C11orf61_BC024479, thus leading to the inhibition of C11orf61_BC024479's activity. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
A broad inhibitor of protein kinase C (PKC) isoforms. Go6983 would inhibit PKC activity, potentially affecting C11orf61_BC024479 if it is regulated by PKC-mediated signaling, resulting in decreased activation of C11orf61_BC024479 due to a lack of PKC signaling. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
A GSK-3 inhibitor. By inhibiting GSK-3, SB216763 could affect signaling pathways that involve GSK-3, potentially including those in which C11orf61_BC024479 is involved, leading to decreased functional activity of C11orf61_BC024479. | ||||||